This study investigates a therapeutic antibody targeting TREM2, a receptor expressed in microglia, the brain’s resident immune cells. The antibody stimulates microglial proliferation and survival, offering a potential strategy for modulating immune responses in neurodegenerative diseases like Alzheimer’s.